Price to Operating Profit (P/OP)
since 2005
Paying user area
Try for free
Celgene Corp. pages available for free this week:
- Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Profitability Ratios
- Analysis of Liquidity Ratios
- Operating Profit Margin since 2005
- Return on Equity (ROE) since 2005
- Return on Assets (ROA) since 2005
- Debt to Equity since 2005
- Total Asset Turnover since 2005
- Price to Earnings (P/E) since 2005
- Analysis of Debt
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Celgene Corp. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Calculation
Celgene Corp., P/OP, long-term trends, calculation
| P/OP | = | Share price1, 2, 3 | ÷ | Operating profit per share1 | Operating profit per share1 | = | Operating income (loss)1 (in millions) |
÷ | No. shares of common stock outstanding2 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 26, 2019 | = | ÷ | = | ÷ | |||||||
| Feb 7, 2018 | = | ÷ | = | ÷ | |||||||
| Feb 10, 2017 | = | ÷ | = | ÷ | |||||||
| Feb 11, 2016 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2015 | = | ÷ | = | ÷ | |||||||
| Feb 13, 2014 | = | ÷ | = | ÷ | |||||||
| Feb 15, 2013 | = | ÷ | = | ÷ | |||||||
| Feb 22, 2012 | = | ÷ | = | ÷ | |||||||
| Mar 1, 2011 | = | ÷ | = | ÷ | |||||||
| Feb 18, 2010 | = | ÷ | = | ÷ | |||||||
| Feb 17, 2009 | = | ÷ | = | ÷ | |||||||
| Feb 20, 2008 | = | ÷ | = | ÷ | |||||||
| Feb 27, 2007 | = | ÷ | = | ÷ | |||||||
| Mar 15, 2006 | = | ÷ | = | ÷ |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).
1 US$
2 Data adjusted for splits and stock dividends.
3 Closing price as at the filing date of Celgene Corp. Annual Report.
- Share Price Trend
- The share price demonstrated a generally upward trajectory from March 2006 through February 2019, increasing from $20.5 to a peak of $123.43 in February 2015. After this peak, the share price experienced some volatility, declining to $89.71 by February 2019. Notably, the price surged significantly between 2012 and 2015, reflecting strong market confidence during this period.
- Operating Profit Per Share (OPPS)
- Operating profit per share showed a positive growth trend overall, moving from $0.12 in March 2006 to $7.39 by February 2019. Despite a substantial negative value of -$1.59 in February 2009, the metric recovered quickly, indicating a profitability rebound. This oscillation suggests some operational challenges around 2009 but generally improving profitability thereafter, with particularly notable increases post-2014.
- Price to Operating Profit Ratio (P/OP)
- The P/OP ratio displayed considerable fluctuation, starting very high at 169.22 in March 2006 and generally declining over time to 12.13 by February 2019. Missing data for the 2009 period prevents full trend analysis during that year, but the overall reduction in this ratio indicates that the share price has become more reasonably valued relative to operating profit. Sharp declines in this ratio after 2015 suggest that operating profit growth outpaced share price increases, potentially indicating improved earnings efficiency or market valuation adjustments.
- Overall Financial Insight
- The data reflect a company with growing profitability and an initial period of high valuation multiples that moderated over time. The rapid increase in operating profit per share following the 2009 dip underscores effective management or operational strategies leading to enhanced profitability. Market valuation, as indicated by the P/OP ratio, appears to have become more aligned with fundamental operating earnings, especially after 2015, suggesting a maturing perception of the company’s value. Share price volatility in recent years merits attention but remains significantly above early-period levels.
Comparison to Competitors
Celgene Corp., P/OP, long-term trends, comparison to competitors
| Celgene Corp. | AbbVie Inc. | Amgen Inc. | Danaher Corp. | Gilead Sciences Inc. | Regeneron Pharmaceuticals Inc. | Thermo Fisher Scientific Inc. | Vertex Pharmaceuticals Inc. | |
|---|---|---|---|---|---|---|---|---|
| Feb 26, 2019 | ||||||||
| Feb 7, 2018 | ||||||||
| Feb 10, 2017 | ||||||||
| Feb 11, 2016 | ||||||||
| Feb 20, 2015 | ||||||||
| Feb 13, 2014 | ||||||||
| Feb 15, 2013 | ||||||||
| Feb 22, 2012 | ||||||||
| Mar 1, 2011 | ||||||||
| Feb 18, 2010 | ||||||||
| Feb 17, 2009 | ||||||||
| Feb 20, 2008 | ||||||||
| Feb 27, 2007 | ||||||||
| Mar 15, 2006 |
Based on: 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31), 10-K (reporting date: 2016-12-31), 10-K (reporting date: 2015-12-31), 10-K (reporting date: 2014-12-31), 10-K (reporting date: 2013-12-31), 10-K (reporting date: 2012-12-31), 10-K (reporting date: 2011-12-31), 10-K (reporting date: 2010-12-31), 10-K (reporting date: 2009-12-31), 10-K (reporting date: 2008-12-31), 10-K (reporting date: 2007-12-31), 10-K (reporting date: 2006-12-31), 10-K (reporting date: 2005-12-31).